Xarxa de bancs de tumors de Catalunya

  • Increase font size
  • Default font size
  • Decrease font size

Hospital Josep Trueta

Correu electrònic Imprimeix PDF

 

Investigadors Responsables: Aquesta adreça electrònica s'està protegint contra robots de correu brossa, necessiteu que el JavaScript estigui habilitat per a mostrar-la Aquesta adreça electrònica s'està protegint contra robots de correu brossa, necessiteu que el JavaScript estigui habilitat per a mostrar-la

Descripció

Nom del Banc: Biobanc IDIBGi - Banc de Tumors ICO - Hospital Universitari Dr. Josep Trueta, Girona

Centre: Servei d'Anatomia Patològica - Hospital Universitari Dr. Josep Trueta, Girona

Institució: IDIBGi, ICO, Hospital Universitari Dr. Josep Trueta, Girona

Breu Descripció: Col·lecció de mostres de teixit tumoral i no tumoral congelades i parafinades.

Personal

Nom Títol Categoria

Aquesta adreça electrònica s'està protegint contra robots de correu brossa, necessiteu que el JavaScript estigui habilitat per a mostrar-la Dr.

Llic Med Patòleg. Investigador Responsable del Banc de Tumors (BT).

Aquesta adreça electrònica s'està protegint contra robots de correu brossa, necessiteu que el JavaScript estigui habilitat per a mostrar-la Dra.

Biòleg. Tècnic Responsable Gestió del Banc de Tumors

Aquesta adreça electrònica s'està protegint contra robots de correu brossa, necessiteu que el JavaScript estigui habilitat per a mostrar-la

Dr.

Llic Med Oncòl. Cap de Servei d' Oncol Med. Investigador BT

     

Activitats

  • Proporcionar mostres pels estudis de recerca als investigadors que ho solicitin
  • Preparar i tallar les mostres

Fons

El Banc de Tumors recull principalment mostres de tumors de les neoplàsies més freqüents i teixit normal associat.

Tipus de mostres:

  • Fragments de teixit congelat
  • Blocs de parafina amb material fixat

Publicacions

  • Fatty acid synthase expression is strongly related to menopause in early-stage breast cancer patients. Porta R, Blancafort A, Casòliva G, Casas M, Dorca J, Buxo M, Viñas G, Oliveras G, Puig T. Menopause 2013. DOI: 10.1097/gme.0b013e31829d17dc.
  • α2,3-sialyltransferase ST3Gal IV promotes migration and metastasis in pancreatic adenocarcinoma cells and tends to be highly expressed in pancreatic adenocarcinoma tissues. Pérez-Garay M, Arteta B, Llop E, Cobler L, Pagès L, Ortiz R, Ferri MJ, de Bolós C, Figueras J, de Llorens R, Vidal-Vanaclocha F, Peracaula R. Int J Biochem Cell Biol 2013; (8):1748-57. DOI: 10.1016/j.biocel.2013.05.015
  • Different fatty acid metabolism effects of (-)-Epigallocatechin-3-Gallate and C75 in adenocarcinoma lung cancer. Relat j, Blancafort A, Oliveras G, Cufí S, Haro D, Marrero PF, Puig T. BMC Cancer 2012; 12(1):280. DOI:10.1186/1471-2407-12-280 .
  • Comparison of molecular analysis and histopathology for axillary lymph node staging in primary breast cancer: results of the B-CLOSER-I study. Bernet L, Rojo F, Hardisson D, Córdoba A, Panadés MJ, Velasco A, López-Bonet E, Cano R, Polo L. Diagn Mol Pathol 2012; 21(2):69-76.
  • Epithelial-to-mesenchymal transition (EMT) confers primary resistance to trastuzumab (Herceptin). Oliveras-Ferraros C, Corominas-Faja B, Cufí S, Vazquez-Martin A, Martin-Castillo B, Iglesias JM, López-Bonet E, Martin ÁG, Menendez JA. Cell Cycle 2012; 11(21):4020-32.
  • Ser2481-autophosphorylated mTOR colocalizes with chromosomal passenger proteins during mammalian cell cytokinesis. Vazquez-Martin A, Sauri-Nadal T, Menendez OJ, Oliveras-Ferraros C, Cufí S, Corominas-Faja B, López-Bonet E, Menendez JA. Cell Cycle 2012; 11(22):4211-21.
  • Androgen-independent prostate cancer cells circumvent EGFR inhibition  by overexpression of alternative HER receptors and ligands. Carrion-Salip D, Panosa C, Menendez JA, Puig T, Oliveras G, Pandiella A, De Llorens R, Massaguer A. Int J Oncol 2012; 41(3):1128-38.
  • Prediccion of cervical intraepithelial neoplasia grade 2+ (CIN2+) using HPV DNA testing after a diagnosis of atypical squamous cell of unetermined significance (ASC-US) in Catalonia, Spain. Ibáñez R, Moreno-Crespi J, Sardà M, Autonell J, Fibla M, Gutiérrez C, Lloveras B, Alejo M, Català I, Alameda F, Casas M, Bosch FX, De Sanjosé S. BMC Infec Dis 2012; 12:25. DOI:10.1186/1471-2334-12-25.
  • Metformin limits the tumourigenicity of iPS cells without affecting their pluripotency. Vazquez-Martin A, Cufi S, Lopez-Bonet E, Corominas-Faja B, Oliveras-Ferraros C, Martin-Castillo B, Menendez JA. Sci Rep 2012; 2:964. DOI: 10.1038/srep00964.
  • New synthetic inhibitors of fatty acid synthase with anticancer activity. Turrado C, Puig T, Garcia-Cárceles J,Artola M, Benhamú B, Ortega-Gutiérrez S, Relat J, Oliveras G, Blancafort A, Haro D, Marrero PF, Colomer R, López-Rodríguez ML. J Med Chem 2012; 55(11):5013-23.
  • Epidemiologia del Cáncer de Cérvix in situ e Invasor en la Provincia de Girona 1990 - 2004: Incidencia, Mortalidad, Supervivencia e Historial de CribadoCastro Marqueta, Pilar; Moreno Crespi, Judit; Buxó Pujolràs, Maria; Cervantes Amat, Marta; Pérez-Gómez, Beatriz; Marcos-Gragera, Rafael. Med Clin (Barc) 2011; 136(5):192.
  • Population-based incidence and survival of central nervous system (CNS) malignancies in Girona (Spain) 1994-2005Fuentes-Raspall R, Vilardell L, Pérez-Bueno F, Joly C, Garcial-Gil M, Garcia-Velasco A, Marcos-Gragera R. J Neurooncol 2011; 101(1): 117-23.
  • Diagnostic utility of mammaglobin and GCDFP-15 in the identification of primary neuroendocrine carcinomas of the breast. López-Bonet E, Pérez-Martinez MC, Martín-Castillo B, Alonso-Ruano M, Tuca F, Oliveras-Ferraros C, Cufí S, Vazquez-Martin A, Beltrán M, Bernadó L, Menéndez JA. Breast Cancer Res Treat 2011; 126(1):241-5.
  • Expression status of the autophagy-regulatory gene ATG6/BECN1 in ERBB2-positive breast carcinomas: by passing ERBB-induced oncogenic senescence to regulate the efficacy of ERBB2-targeted therapies. Vazquez-Martin A, Cufí S, Oliveras-Ferraros C, Martín-Castillo B, Del Barco S, López-Bonet E, Menéndez JA. Genes Chromosomes Cancer 2011; 50(4):284-90.
  • Antibody microarray-based technology to rapidly define matrix metalloproteinase(MMP) signatures in patients undergoing resection for primary gastric carcinomaPuig-Costa M, Oliveras-Ferraros C, Flaquer S, Llopis-Puigmarti F, Pujol-Amado E, Martín-Castillo B, Vazquez-Martin A, Cufí S, Ortiz R, Roig J, Codina-Cazador A, Menéndez JA. J Surg Oncol 2011; 104(1):106-9.
  • Interferon/STAT1 and neuregulin signaling pathways are exploratory biomarkers of cetuximab (Erbitux®) efficacy in KRAS wild-type squamous carcinomas: a pathway-based analysis of whole human-genome microarray data from cetuximab-adapted tumor cell-line modelsOliveras-Ferraros C, Vazquez-Martin A, Queralt B, Adrados M, Ortiz R, Cufí S, Hernández-Yagüe X, Guardeño R, Báez L, Martin-Castillo B, Pérez-Martínez MC, Lopez-Bonet E, De Llorens R, Bernadó L, Brunet J, Menendez JA. Int J Oncol 2011; 39(6):1455-79. DOI: 10.3892/ijo. 2011.1155.
  • A novel inhibitor of fatty acid synthase shows activity against  HER2+ breast cancer  xenografts and is active in anti-HER2 drug-resistant cell lines. Puig T, Aguilar H, Cufí S, Oliveras G, Turrado C, Ortega-Gutiérrez S, Benhamú B, López-Rodríguez ML, Urruticoechea A, Colomer R. Breast Cancer Res 2011; 13(6):R131.
  • Neuroendocrine tumors: A population-based study of incidence and survival in Girona province, 1994-2004. Alsina M, Marcos-Gragera R, Capdevila J, Buxó M, Ortiz MR, Barretina P, Vilardell L, Brunet J, Beltran M, Izquierdo A. Cancer Epidemiology 2011;  35:49-54.
  • Incorporating the antidiabetic drug metformin in HER2-positive breast cancer treated with neo-adjuvant chemotherapy and trastuzumab: an ongoing clinical-translational research experience at the Catalan Institute of OncologyMartín-Castillo B, Dorca J, Vazquez-Martin A, Oliveras-Ferraros C, López-Bonet E, Garcia M, Del Barco S, Menéndez JA. Int J Oncol 2010; 21(1):187-9.
  • Serine 2481-autophosphorylation of mammalian target of rapamycin(mTOR) couples with chromosome condensation and segregation during mitosis: confocal microscopy characterization and immunohistochemical validation of PP-mTOR(Ser2481) as a novel high-contrast mitosis marker in breast cancer core biopsies. López-Bonet E, Vazquez-Martin A, Pérez-Martinez MC, Oliveras-Ferraros C, Pérez-Bueno F, Bernadó L, Menéndez JA. Int J Oncol 2010; 36(1):107-15.
  • Discordant expression of molecular markers between primary and nodal metastases: a histopathological manifestation of the ‘self(stem cell)-seeding' nature of breast cancer disease? López-Bonet E, Menéndez JA. Ann Oncol 2010; 21(4):901-2.
  • Pathway-focused proteomic signatures in HER2-overexpressing breast cancer with a basal-like phenotype: new insights into de novo resistance to trastuzumab (Herceptin)Oliveras-Ferraros C, Vazquez-Martin A, Martín-Castillo B, Pérez-Martinez MC, Cufí S, Del Barco S, Bernadó L, Brunet J, López-Bonet E, Menéndez JA. Int J Oncol 2010; 37(3):669-78.
  • Novel anti-fatty acid synthase compounds with anti-cancer activity in HER2+ breast cancer. Oliveras G, Blancafort  A, Urruticoechea  A, Campuzano O, Gómez-Cabello D, Brugada R, López-Rodríguez ML, Colomer R, Puig T. Ann NY Acad Sci 2010; 1210:86-92.
  • Impacto de la obesidad en las caraterísticas anatomopatológicas de los tumores colorrectales. Estudio observacional. Garcia-Oria MJ, Armengol M, Ortiz R, Codina-Cazador A. Cir Esp 2010; 87(1):33-8.
  • Mitotic kinase dynamics of the active form of AMPK (phosphor-AMPK alphaThr172) in human cancer cells. Vazquez-Martin A, López-Bonet E, Oliveras-Ferraros C, Pérez-Martinez MC, Bernadó L, Menéndez JA. Cell Cycle. 2009; 8(5):788-91.
  • Merkel cell cancer of the skin: population-based incidence and survival, 1995-2005 Vilar-Coromina N, Pérez Bueno F, Alsina Maqueda M, Vilardell Gil L, Izquierdo Font A, Marcos-Gragera R. Med Clin(Barc) 2009; 132(18):701-3.
  • Peripheral zone prostate cancer in patients with elevated PSA levels and low free-to-total PSA ratio: detection with MR imaging and MR spectroscopy. Vilanova JC, Comet J, Barceló-Vidal C, Barceló J, López-Bonet E, Maroto A, Arzoz M, Moreno A, Areal J. Radiology 2009; 253(1):135-43.
  • Solid neuroendocrine breast carcinomas: incidence, clinico/pathological features and immunohistochemical profiling. López-Bonet E, Alonso-Ruano M, Barraza G, Vazquez-Martin A, Bernadó L, Menendez JA. Oncol Rep. 2008; 20(6):1369-74.

Equip i tècniques

  • Congelador de -80ºC
  • Congelador ultraràpid per teixits (Clini-RF)
  • Tissue microarrayer (aparell per a la realització de matrius de teixit en parafina)
  • Tallar i preparar les mostres sol.licitades
  • Realització de matrius de teixit en parafina (arrays parafina)

Altres